Counterpoint Biomedica

Counterpoint Biomedica is a private, preclinical-stage biotech firm developing advanced tumor-targeting platforms designed to retrofit existing FDA-approved oncology drugs, improving their precision, efficacy, and safety profile. The company leverages a foundational technology known as Pathotropic (XC-Targeting), which homes in on exposed collagen signatures in tumors, a platform historically validated in clinical gene therapy trials. With an extensive pipeline focused on combination therapies and diagnostics, Counterpoint aims to reduce clinical development costs and timelines for improved cancer treatments while recently securing new patents for targeted pharmaceuticals, cancer stem cell capture, and immunotherapy.

Proprietary Pathotropic (XC-Targeting) platform that utilizes exposed collagenous signatures in the tumor microenvironment for precise, disease-seeking delivery of therapeutic and diagnostic agents.

Competes with numerous companies in targeted drug delivery, including developers of antibody-drug conjugates (ADCs), nanoparticle therapies, and other ligand-directed platforms. Its differentiation lies in targeting exposed collagen signatures (XC) and a retrofit model for approved drugs.